Billionaire Singer threatens to sue AbbVie over Shire breakup

Carly Helfand A $ 1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $ 55 billion agreement. But investors? At least one ...

Shire’s tax model under scrutiny, KDEV cozies up to Asian conglomerate, Onxeo heads to PhIII

Nick Paul Taylor In this week's EuroBiotech Report, after a brief post-AbbVie deal lull in discussion of Shire's tax rate, the Irish-headquartered drugmaker found its financial ...

FDA advisers spurn Novartis’ blood cancer drug, putting approval in doubt

Damian Garde Novartis' new multiple myeloma is treatment too risky to be approved, a group of FDA advisers voted, dealing a blow to the drugmaker and its hopes of launching the ...

FDA yanks Ranbaxy’s tentative approval for generic Nexium

Eric Palmer At about the same time that AstraZeneca CEO Pascal Soriot was telling investors its earnings had been boosted because no generic of blockbuster Nexium had appeared, Ranbaxy ...

Can J&J score sales with FDA’s new Olysio-plus-Sovaldi approval?

Tracy Staton Johnson & Johnson just scored a marketing goal: Its hepatitis C drug Olysio won FDA approval as part of a two-drug cocktail that also stars Gilead Sciences' Sovaldi. ...

Spark snags a ‘breakthrough’ tag for its Phase III gene therapy

Damian Garde Gene therapy startup Spark Therapeutics has picked up the FDA's coveted breakthrough-therapy designation for its lead candidate, a one-time treatment that promises ...

New numbers back the meme: Pharma does spend more on marketing than R&D

Tracy Staton FiercePharma News

Actavis bid looms as Allergan says it’s been approached (again) on merger

John Carroll Allergan today confirmed what much of the industry has been buzzing about for some time now: It's in takeover discussions with another company other than the acquisition-hungry ...

Merck partners with Bind on a pair of new cancer drug programs

John Carroll Four months after Bind Therapeutics lost marquee development partner Amgen, Merck has stepped up to take the Big Biotech's place in the lineup. The pharma giant, which ...

French Smith & Nephew CEO Olivier Bohuon seen as solid pick for top Sanofi job

Eric Palmer Olivier Bohuon, the CEO of artificial hip and knee maker Smith & Nephew may have a leg up over other potential candidates to take the reins of drugmaker Sanofi after ...

Allergan loses fight to block Ackman from voting for a Valeant takeover

Carly Helfand Valeant and partner Bill Ackman have dodged a serious roadblock in their quest to acquire Allergan. A 9.7% roadblock, if you will. FiercePharma News

Actavis rides success of branded drugs and M&A to positive Q3

Emily Wasserman Actavis has been inking deals with Forest Laboratories and Warner Chilcott to get its hands on the companies' suite of branded products. Now, the company is celebrating ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS